Contribution by NRF2 upregulation to lung carcinogenesis, and the possible therapeutic value of NRF2 inhibition by GSK-3

Harrison, David (PI)

School of Medicine

Project: Standard

Acronym	Contribution by NRF2 upregulation
Status	Finished
Effective start/end date	1/05/16 → 31/10/19

Funding

Medical Research Council: £108,141.83

Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacological activation of Nrf2 (NF-E2-related factor 2)
Sharma, R. S., Harrison, D. J., Kisielewski, D., Cassidy, D. M., McNeilly, A. D., Gallagher, J. R., Walsh, S. V., Honda, T., McCrimmon, R. J., Dinkova-Kostova, A. T., Ashford, M. L. J., Dillon, J. F. & Hayes, J. D., 13 Dec 2017, (E-pub ahead of print) In: Cellular and Molecular Gastroenterology and Hepatology. 5, 3, p. 367-398 32 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File